FELLOWSHIP : Division of Endocrinology, Diabetes, and Metabolic Diseases
Department of Medicine – Thomas Jefferson University Hospital, Philadelphia, PA – USA

RESIDENCY : Internal Medicine
Department of Medicine – Thomas Jefferson University Hospital, Philadelphia, PA – USA

M.D. Georgetown University School of Medicine
Washington, DC – USA

M.S. (Physiology), Georgetown University
Washington, DC – USA

B.S. (Biology), American University of Beirut
Beirut, Lebanon

• OSTEOS (founding member)
  (Member of the Executive Committee, April 2006 – April 2007)
• Lebanese Society of Diabetology
• Lebanese Society of Endocrinology, Diabetology, and Lipidology
  (Member of the Executive Committee, July 2002 – July 2006)
• American Association of Clinical Endocrinologists
• American Diabetes Association
• Pennsylvania Medical Society

• Type 2 Diabetes: From Prevention to Treatment, January 2007. Beirut, Lebanon.
• Prevention of Diabetes in High-Risk Patients: The Role of Antihypertensives, May 2006. Beirut, Lebanon.
• Glucose Intolerance in the Mentally Ill, May 2006. Cairo, Egypt.
• Treatment of Postprandial Hyperglycemia: Point – Counterpoint, April 2006. Beirut, Lebanon.
• Management of Insulin Resistance in Type 2 Diabetes Mellitus, February 2006. Dbayeh, Lebanon.
• Screening, Diagnosis, and Management of Type 2 Diabetes, Pharmacists Congress, February 2006. Beirut, Lebanon.
• Is There a Metabolic Syndrome? February 2006. Beirut, Lebanon.
• Inpatient Hyperglycemia: Do We Need to Treat? January 2006. Zahle, Lebanon.
• Effective Strategies to Improve Glycemic Control in Type II Diabetes, January 2006. Tripoli, Lebanon.
• Metabolic Syndrome Case Discussion, December 2005. Beirut, Lebanon.
• When and How to Treat Postmenopausal Osteoporosis, May 2005.
• Paphos/Larnaca, Cyprus and Beirut, Lebanon.
• Management of Hypertension and Albuminuria in Diabetes, May 2005. Beirut, Lebanon.
• Clinical Use of Recombinant Human PTH in the Management of Postmenopausal Osteoporosis, May 2005. Limassol/Larnaca, Cyprus.
• When and How to Treat Postmenopausal Osteoporosis, April 2005. Valletta, Malta.
• Clinical Use of Recombinant Human PTH in the Management of Postmenopausal Osteoporosis, April 2005. Valletta, Malta and Al-Ain, UAE.
• Managing Endocrine Issues in the Mentally Ill, March 2005. Dbayeh, Lebanon.
• Insulin Therapy in Hospitalized Patients, February 2005. Amman, Jordan.
• Lebanese Guidelines on Osteoporosis. Presentation to the Lebanese Society of Endocrinology, January 2005. Beirut, Lebanon.
• Cholesterol Lowering – A critical Consideration in Patients with Diabetic Dyslipidemia, December 2004. Dubai/AbuDhabi, UAE.
• Inpatient Hyperglycemia: Do We Need to Treat ? First Annual Scientific Meeting of the Syrian, Iraqi, Lebanese, and Jordanian Diabetes Associations, November 2004. Aleppo, Syria.
• Prevention of Fractures in Postmenopausal Osteoporosis, June 2004. St. George Hospital, Beirut, Lebanon.
• Prevention of Fractures in Postmenopausal Osteoporosis, Internal Medicine Congress, May 2004. Tehran, Iran.
• New Alternatives in the Management of Insulin Resistance in Type II Diabetes, April 2004. Kuwait City, Kuwait.
• Prevention of Fractures in Postmenopausal Osteoporosis, March 2004. Beirut, Lebanon and Larnaca/Paphos, Cyprus.
• Inpatient Hyperglycemia: Do We Need to Treat ? March 2004. Beirut, Lebanon.
• Management of Benign Multinodular Goiter, February 2004. Surgery Congress, Haroun Hospital, Lebanon.
• New Alternatives in the Management of Insulin Resistance in Type II Diabetes, January 2004. Abu Dhabi/Dubai, UAE.
• Role of Metformin in the Treatment and Prevention of Type II Diabetes, January 2004. St. George Hospital, Beirut, Lebanon.
• Managing Type 2 Diabetes in General Practice, December 2003. Lebanese – Order of Physicians, Beirut, Lebanon.
• Prevention of Diabetic Nephropathy, November 2003. World Diabetes Day, Beirut, Lebanon.
• Clinical Outcomes in Postmenopausal Women, October 2003. OB-GYN Congress, Tehran, Iran.
• Clinical Outcomes in Postmenopausal Women – Looking Beyond the Bone, September 2003. PanArab Rheumatology Congress, Beirut, Lebanon.
• Treatment of Dyslipidemia in Type 2 Diabetes – Insights from the HPS, September 2003. Beirut, Lebanon.
• Management of Hypertension in Type 2 Diabetes – Evidence Based Medicine, August 2003. Beirut, Lebanon.
• Management of Diabetes in Hospitalized Patients, May 2003. Crete, Greece.
• The role of Fluvastatin ER in dyslipidemias: focus on diabetics. May 2003. Beirut, Lebanon.
• Clinical Issues in the Management of Postmenopausal Osteoporosis, March/April/May 2003. Beirut, Lebanon.
• Management of Diabetes in Hospitalized Patients, February 2003. Beirut, Lebanon.
• Clinical Issues in the Management of Postmenopausal Osteoporosis, December 2002. Larnaca/Paphos, Cyprus.
• Glucose Intolerance in the Mentally Ill, November 2002. Istanbul, Turkey.
• Glucose Intolerance in the Mentally Ill, October 2002. Beirut, Lebanon.
• Selection of Therapy in Postmenopausal Osteoporosis, June 2002. Amman, Jordan.
• Selection of Therapy in Postmenopausal Osteoporosis, June 2002. St. George Hospital, Beirut, Lebanon.
• The role of Fluvastatin ER in dyslipidemias: focus on diabetics. May 2002. St. George Hospital, Beirut, Lebanon.
• Cardiovascular Outcomes in Postmenopausal Women. March 2002. Istanbul, Turkey.
• Effets Extra-osseux du Raloxifène, January 2002. Algiers, Algeria.
• Selection of Therapy in Postmenopausal Osteoporosis, November 2001. Valletta, Malta.
• Selection of Therapy in Postmenopausal Osteoporosis, November 2001. Hotel-Dieu de France, Beirut, Lebanon.
• Clinical Implications of Postprandial Hyperglycemia, October 2001. PanArab Endocrinology Congress, Damascus, Syria.
• Diabetes and Hypertension, October 2001. Batroun, Lebanon.
• SERMS: from Clinical Trials to Clinical Practice, June 2001. Tripoli, Lebanon.
• Prevention and treatment of Postmenopausal Osteoporosis. Trad Hospital, February 2001. Beirut, Lebanon.
• Thyroid Disease in Pregnancy, December 2000. St. George’s Hospital, Beirut, Lebanon.
• Postprandial Hyperglycemia: Needs for Better Control, November 2000. Dubai/Abu Dhabi, UAE.
• Reduction of Hypoglycemia with Insulin Analogs. Pan Arab Endocrinology Congress, October 2000. Amman, Jordan.
• Raloxifene in the Treatment of Postmenopausal Osteoporosis, October 2000. Damascus, Syria.
• Round Table Discussion on Diabetes with Lebanese, Syrian, and Jordanian Endocrinologists, May 2000. Limassol, Cyprus.
• Prevention and Treatment of Osteoporosis. Dubai Pharmaceutical and Industrial Technology Scientific Meeting, November 1999. Dubai, UAE.
• Role of Lispro in Type I and Type II Diabetes, November 1999. Kuwait City, Kuwait.
• Clinical Experience with Raloxifene, November 1999. Kuwait City, Kuwait.
• Raloxifene: A New Choice for Postmenopausal Women’s Health, July 1999. Beirut, Lebanon and La Valletta, Malta.
• Implications of the UKPDS study, March 1999. Beirut, Lebanon.
• Round Table Discussion on Diabetes with Lebanese Endocrinologists, March 1999. Beirut, Lebanon.
• Implications of the UKPDS study. February 1999. Damascus, Syria.
• Raloxifene, A New Choice for Postmenopausal Women’s Health, Pan Arab Pharmacy Congress, October 1998. Jbeil, Lebanon.

• Almawi WY, Wakim-Ghorayeb SF, Arekat MR, Najm P, Keleshian SH, Al- Sayed N, Blanchon B, Samaha HR, Irani-Hakime N. Association of Selective HLA Class II Susceptibility-Conferring and Protective Haplotypes with Type 2 Diabetes in Patients from Bahrain and Lebanon. Clin Vaccine Immunol. 2006; 13(11): 1296-98.
• Wakim-Ghorayeb SF, Keleshian SH, Timson G, Finan RR, Najm P, Irani- Hakime N,. Almawi WY. Factor V G1691A (Leiden) and Prothrombin G20210A Single-Nucleotide Polymorphisms in Type II Diabetes Mellitus. American Journal of Hematology 2005; 79: 1-3.
• Al-Jenaidi FA, Wakim-Ghorayeb SF, Al-Abbasi A, Arekat MR, Irani-Hakime N, Najm P, Al-Ola K,. Motala AA, Almawi WY. Contribution of Selective HLA- DRB1/DQB1 Alleles and Haplotypes to the Genetic Susceptibility of Type 1 Diabetes among Lebanese and Bahraini Arabs. J. Clin. Endocrinol. Metab., Sep 2005; 90: 5104-5109.
• Maalouf N, Wehbe J, Najm P,Chidiac R, Atallah P, Nehme A, Habanbo J, Farah G, Maalouf G. Osteoporosis: Is There a Place for a New Therapeutical Approach? Revue Medicale Libanaise 2003; 15(3): 123-37.
• Maalouf N, Wehbe J, Nehme A, Najm P, Chidiac R, Eid J, Atallah P, Adib G, Maalouf G. Osteoporosis: Combination Therapy for Better or Worse. J Musculoskel Neuron Interact 2003; 3(2): 141-47.
• Kabalan S, Abdallah C, Weitckus S, Kratky P, Pavo I, Najm PS, Berbari A. Clinical Study to Evaluate the Antihypertensive Efficacy of Moxonidine. BMJ Middle East 2000; 7: 6-9.
• Ohanessian JP, Marco CC, Najm PS, Goldstein BJ, Caro JF, Kolaczynski JW. Small Weight Gain Is Not Associated with Development of Insulin Resistance in Healthy, Physically Active Individuals. Horm Metab Res. 1999; 31(5): 323-25.
• Najm PS, dePapp AE, Ruby EB. A 37 Year-Old Female with A Shoulder Mass and Hypertensive Crisis. J Clin Endocrinol Metab. 1997; 82(12): 3972-75.

• Participated as principal investigator in the following clinical trials :
  • Hyperglycemia and its Effect after Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes (HEART2D).
  • A Trial comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects with Uncontrolled Blood Sugar (ATLANTUS study).
• Participated as co-investigator in the following clinical trials :
  • A 14-Week Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pregabalin (150-600 mg/day) Using a Flexible, Optimized Dose Schedule in Patients with Painful Diabetic Neuropathy.
  • PRECOSE : Resolution of Optimal Titration to Enhance Current Therapies.
  • A 52-Week, Multicenter, Controlled, Randomized, Open Clinical Trial Comparing HOE901 Insulin with NPH Human Insulin in Subjects with Type I Diabetes.
• Participated as sub-investigator in the following clinical trials :
  • A Placebo-Controlled Safety and Efficacy Study of Pimagidine in Diabetic Patients with Overt Nephropathy.
  • Repaglinide in Type II Diabetes : A Placebo-Controlled, Double-Blind, Randomized, Six Month Fixed Dose Safety Study.
  • A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multidose Study of the Safety & Pharmacokinetic/Pharmacodynamic Effects of rhIGF-I in Combination with Insulin for treatment of NIDDM.
  • A Phase IIIA, Randomized, Double-Blind, Placebo-Controlled, Multicenter Comparison Study to Evaluate the Safety, Efficacy, and Tolerability of BRL49635C Therapy when Administered to patients with NIDDM.
  • A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Measuring the Effects of Troglitazone with or without Insulin on reaching a Treatment Target in NIDDM Patients Requiring Insulin.
  • A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Multidose Study of the Combined Effects of Subcutaneously Administered Insulin and rhIGF-I in Subjects with IDDM.
  • A 26-Week, Randomized, Double-Blind, Double-Dummy,Multicentered Study to Evaluate the Efficacy, Safety and Tolerability of BRL49635C when Administered to Patients with NIDDM Who Are Inadequately Controlled on a Maximal Dose (20mg/day) of Glyburide.